Author: admin

Té Sana Unveils Wellness Products to Manage Anxiety and Menopause

Dr. Lisa Cortez pairs wellness products with a meditation center for holistic treatment

A cup of tea with a wooden spoon and bowls of tea Description automatically generated

HOUSTON – May 7, 2025 – Té Sana has developed a holistic approach to wellness with their Pure Wellness Collection. This collection boasts non-toxic skincare products, therapeutic teas, and mindfully crafted candles for women navigating symptoms of anxiety, perimenopause, and menopause. Té Sana’s wellness products are infused with high-quality organic ingredients to support healthy skin and essential oils to calm the mind. With this collection, Té Sana founder Dr. Lisa Cortez (The Anxiety Dr) has created a beautiful intersection between mental wellness and clean beauty.

Skincare and wellness products are notorious for containing hormone disruptors and toxic ingredients, thereby unleashing chaos on women’s bodies in addition to disrupting their mental wellness. Dr. Lisa Cortez has drawn from 25 years of treating patients with anxiety and her certification in herbalism to create products that support both inner peace and outer radiance. All the products from her Pure Wellness Collection are free of harsh chemicals, fillers, paraffins, phthalates, and fragrances.

“I’ve seen thousands of anxiety patients who have eliminated or swapped out products with clean products, and I see the difference,” says Dr. Lisa Cortez. “I specialize in a holistic approach to anxiety, and those patients who follow this approach usually get better faster.”

By using clean organic oils, butters, essential oils, and tallow, Dr. Lisa Cortez supplies clean products formulated specifically to help manage anxiety and menopausal symptoms. When paired with her guided meditation sessions, these products offer her clients an effective approach to wellness – one that prioritizes both mind and body.

To complement the effectiveness of her wellness products, Dr. Lisa Cortez is planning to open a wellness sanctuary. This physical location will be home to a meditation center where clients can enjoy guided meditation sessions and wellness workshops. It will also function as a retail space where clients can purchase and experience products from the Pure Wellness Collection in person.

With the launch of Té Sana’s wellness sanctuary, Dr. Lisa Cortez will bring her holistic treatment to more women struggling with anxiety, perimenopause, and menopause symptoms. As it expands, Té Sana is ensuring that a more effective approach to wellness is within reach for women in Houston.

About Té Sana Wellness

Té Sana Wellness offers a holistic approach to managing anxiety, perimenopausal, and menopausal symptoms. By drawing from founder Dr. Lisa Cortez’s experience with anxiety treatment and certification in herbalism, Té Sana’s wellness products and meditation center deliver both peace of mind and physical wellness.

For more information visit https://www.tesanawellness.com

Media Contact
Company Name: Té Sana Wellness
Contact Person: Dr. Lisa Cortez
Email: Send Email
State: Texas
Country: United States
Website: https://www.tesanawellness.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Té Sana Unveils Wellness Products to Manage Anxiety and Menopause

Announcing A Free Online Masterclass: The Four Steps to Reclaim Your Story and Revitalize Your Writing with Nadia Colburn, Ph.D., RYT 200

Join award-winning poet and teacher Nadia Colburn, Ph.D., RYT 200, for a Free Online Masterclass: The Four Steps to Reclaim Your Story and Revitalize Your Writing. Learn an integrative approach combining writing, mindfulness, and yoga. Open to all levels and genres. Offered live May 6–8 at various times. Includes Q&A and generative writing. Sign up to attend live or receive the recording. See more at nadiacolburn.com

Award-winning poet, memoirist, writing teacher, yogi, and activist, Nadia Colburn, Ph.D., RYT 200, who runs an online creative writing school, is excited to announce A Free Online Masterclass: The Four Steps to Reclaim Your Story and Revitalize Your Writing.

In this free live masterclass, Nadia will share her unique integrative approach to writing that combines literary study, creative writing, meditation and yoga.

This class is for writers of all levels – from beginners to professionals – and for writers in any genre. Whether you write memoir, fiction, poetry, or work in other genres, this class will meet you where you are and give you the tools you need to revitalize your writing from the inside out.

The class will be offered live online at three different times and will last 75-90 minutes, depending on the number of questions Nadia gets at the end:

  • Tuesday, May 6th at 7pm ET/ 4pm PT

  • Wednesday May 7th at 3pm ET/ 12pm PT

  • Thursday May 8th at 12pm ET/ 9am PT

Reserve your seat in the FREE Masterclass: Four Steps to Reclaim Your Story and Revitalize Your Writing here. Choose the time that works best for you. If you can’t make it live, sign up for Thursday’s class to receive the recording.

Over the course of the seminar, Nadia will explain how to avoid the three most common mistakes writers make, how to use four essential steps to bring your writing to the next level, how to unite mind and body for more powerful writing, how come into greater flow and vision as a writer, how to heal your story (without getting retraumatized), and how to come into a peaceful, empowering, and fulfilling creative life.

There will be time for generative writing in the session and time for questions and answers with Nadia Colburn (Q&A) at the end.

Nadia Colburn is an award-winning poet and memoir writer, and the author of two poetry books. She has taught literature at MIT, holds a PhD in English from Columbia University, and is a certified yoga teacher and mindfulness instructor. Her online community of students includes over 35,000 mindful writers.

Learn more about Nadia Colburn’s Online Writing Classes in Boston

Media Contact
Company Name: Nadia Colburn
Contact Person: Nadia Colburn
Email: Send Email
Phone: (617) 785-6627
Address:48 Cedar St
City: Cambridge
State: Massachusetts
Country: United States
Website: https://nadiacolburn.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Announcing A Free Online Masterclass: The Four Steps to Reclaim Your Story and Revitalize Your Writing with Nadia Colburn, Ph.D., RYT 200

Russell Rabichev Named Top Go High Level Affiliate Amid Diverse Business Success

Entrepreneur expands impact across digital platforms, real estate, and clean energy industries.

Los Angeles, CA – Russell Rabichev, a multipreneur known for building scalable business systems across various sectors, has secured a Top 2 affiliate position for Go High Level, a leading software platform for digital marketing professionals. This recognition highlights his expertise in deployment automation tools and process-driven solutions, particularly within the growing referral business space.

Operating across the United States and online markets, Rabichev has cultivated multiple ventures over the past decade, including roles in online real estate, construction management, and clean energy development. His work focuses on developing frameworks that optimize both operational efficiency and customer experience. Rabichev’s strategic mindset and collaborative leadership style have positioned him as a trusted figure among emerging entrepreneurs and established networks alike, including members of the Law of Attraction Mastermind community.

His affiliate success reflects broader efforts to integrate marketing automation into practical applications for small and mid-sized businesses. Through Go High Level, Rabichev has introduced streamlined CRM, lead generation, and client communication systems for a wide base of users across sectors.

In addition to his achievements in digital marketing infrastructure, Rabichev is a contributor to the advancement of solar panel installers networks. He supports partnerships that bridge the gap between renewable energy providers and end users, using digital platforms to reduce project delays and administrative costs. His ability to implement scalable models has strengthened service delivery and coordination among contractors, developers, and homeowners.

See Russell Rabichev discuss his approach to marketing and networking – watch his announcement about a Los Angeles Mastermind

The Top 2 affiliate status was confirmed by Go High Level during the second quarter of 2025. The ranking is based on user engagement metrics, conversion performance, and overall impact on platform adoption. Rabichev’s approach—rooted in measurable value and process-driven execution—has consistently led to positive outcomes for those he collaborates with.

While continuing to lead in his core industries, Rabichev emphasizes system building, accountability, and growth through mentorship. He remains focused on expanding partnerships and applying digital solutions to real-world business challenges.

Ongoing projects in real estate, green construction, and platform-based marketing are expected to further solidify his role as a process innovator in the years ahead.

Media Contact
Company Name: Rabbi
Contact Person: Russell Rabichev
Email: Send Email
Phone: 1 (310) 747-5505
City: Los Angeles
State: Calfiornia
Country: United States
Website: https://rabbi.love/

Dividend Music Group Invests $200,000 in Chicago Youth via the Kam Cares Foundation

Chicago, IL – May 7th, 2025 – Dividend Music Group has announced a $200,000 investment in Chicago youth through the Kam Cares Foundation, a nonprofit organization dedicated to empowering inner city communities with access to vital resources and opportunities. This investment will fund Sound Futures, an innovative new program designed to cultivate the next generation of music industry leaders.

Founded in 2016, the Kam Cares Foundation has made a lasting impact in cities such as Detroit, Chicago, Louisville, and Brooklyn, NY. This latest donation from Dividend Music Group will further expand the foundation’s reach and strengthen its commitment to nurturing the next wave of leaders, artists, and innovators in Chicago.

The donated funds will specifically support recording studio access, marketing training, graphic design services for artwork, free distribution to major platforms like Apple Music and Spotify, financial management training, mentorship, brand building, and artist management for all youth selected for the Sound Futures program. This comprehensive initiative is designed to equip young creatives with the skills and resources needed to thrive in the music industry, fostering both artistic growth and entrepreneurial success.

Set to launch in June 2025, the program will run through June 2028, targeting youth ages 12 to 17. The timeline coincides with the academic summer break, a period when young people often lack structured activities and face increased exposure to negative influences. By providing access to creative resources and mentorship during this critical time, Sound Futures aims to offer a positive and constructive outlet that fosters growth, creativity, and opportunity.

As of July 7, 2024, nearly 1,200 shootings had been reported in Chicago, IL, according to the Chicago Police Department. Programs like Sound Futures serve as proactive efforts to engage youth in safe and enriching experiences that can help shape their futures.

Applications for the Sound Futures program are now open and can be found at kamcarefdn.org.

Kam Cares founder Keefe Ammons found his own path when he was introduced to baseball a year before attending Simeon Career Academy on the South Side of Chicago. Under the guidance of Hall of Fame coach Leroy Franklin, he went on to win two Chicago Public League titles—an experience that helped steer him toward discipline, leadership, and perseverance.

Following a brief stint in professional baseball, Ammons, now 29, has built an impressive investment portfolio that positions him as a contender for virtually any 30 Under 30 list. His work extends beyond philanthropy—through Dividend Music Group, he has played a role in shaping the careers of artists like Myles Erlick, a Universal Music Group signee, and Paulina Singer, who recently signed with EMPIRE and Noir Fever.

“I’m looking forward to seeing Sound Futures develop. Out of everywhere I’ve been—both in business and as an athlete—the only thing missing from where I grew up is resources and opportunity,” said Ammons. “At least one will have access to both.”

Beyond his work in music and philanthropy, Ammons has also represented professional and collegiate athletes, including San Diego Padres prospect Joan Gonzalez and several NCAA athletes navigating Name, Image, and Likeness (NIL) opportunities.

Media Contact
Company Name: Kam Cares Foundation
Contact Person: Jamie Wilson
Email: Send Email
Country: United States
Website: http://kamcarefdn.org

Refresh Renovations Southwest Charlotte Shares Insights on the Latest Home Remodeling Trends

Refresh Renovations Southwest Charlotte Shares Insights on the Latest Home Remodeling Trends
Refresh Renovations, a globally recognized home renovation brand, is proud to offer its insights into the latest home remodeling trends to Southwest Charlotte residents. As the newest branch of this industry leader, Refresh Renovations Southwest Charlotte is dedicated to transforming homes by bringing contemporary design, innovative solutions, and expert craftsmanship to the local community.

Southwest Charlotte, North Carolina – May 7, 2025 – Refresh Renovations, a globally recognized home renovation brand, is proud to offer its insights into the latest home remodeling trends to Southwest Charlotte residents. As the newest branch of this industry leader, Refresh Renovations Southwest Charlotte is dedicated to transforming homes by bringing contemporary design, innovative solutions, and expert craftsmanship to the local community.

Homeowners in Southwest Charlotte are increasingly seeking renovations that blend modern aesthetics with sustainable, functional spaces. According to Refresh Renovations Southwest Charlotte, some of the hottest trends include eco-friendly materials, open-concept designs, smart home features, and luxurious bathrooms that serve as private sanctuaries. The company’s team of experts provides homeowners with the latest trends and guides them through every step of the remodeling process to ensure that each project is both stylish and functional.

The Southwest Charlotte branch offers a variety of specialized remodeling services, including:

– Full Home Remodeling: Comprehensive renovations that reimagine and elevate every corner of a home.

– Kitchen Remodeling: Transform your kitchen into a modern, functional space with high-quality materials and smart layouts.

– Bathroom Renovations: Create a relaxing and luxurious bathroom environment with contemporary designs and premium fixtures.

– Accessory Dwelling Units (ADUs): Add valuable living space with ADUs, perfect for guest suites, rental units, or extended family accommodations.

– Home Additions: Seamlessly expand your living space with thoughtfully designed additions that enhance your home’s value and comfort.

– Basement Renovations: Convert basements into versatile spaces, from home theaters to private gyms or cozy family rooms.

“At Refresh Renovations Southwest Charlotte, we’re excited to bring the latest in home remodeling trends to our clients and offer them expert advice that aligns with their unique visions and lifestyle,” said Neel Patel owner of Refresh Renovations Southwest Charlotte. “Our team is dedicated to providing high-quality, seamless renovation experiences, helping homeowners bring their dream spaces to life while staying informed on the latest industry trends.”

Refresh Renovations Southwest Charlotte prides itself on its transparent process, personalized consultations, and commitment to customer satisfaction. Each project is overseen by a dedicated project manager who ensures clear communication and a smooth workflow from design to completion. By incorporating trending elements like energy-efficient materials and smart home technologies, Refresh Renovations Southwest Charlotte creates customized spaces that are not only beautiful but also designed for today’s modern lifestyle.

With this new location, Refresh Renovations Southwest Charlotte is ready to serve Southwest Charlotte and the surrounding areas, bringing its reputation for excellence to local homes. Whether you’re looking for a full home transformation or a targeted remodel, Refresh Renovations Southwest Charlotte combines the latest trends with unparalleled expertise.

For more information about Refresh Renovations Southwest Charlotte and the services they provide, visit their website or contact Neel Patel at (980) 351-7882.

About Refresh Renovations:

Refresh Renovations is a global leader in home remodeling, with locations across the US, UK, New Zealand, and Australia. The company specializes in high-quality renovations, providing clients with the latest designs, materials, and solutions for their homes.

Media Contact
Company Name: Refresh Renovations Southwest Charlotte
Contact Person: Neel Patel
Email: Send Email
Phone: (980) 351-7882
Address:1251 Arrow Pine Dr c121
City: Charlotte
State: North Carolina
Country: United States
Website: https://maps.app.goo.gl/zK74AiF3psuGNtLe6

Pancreatic Cancer Pipeline Appears Robust With 290+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Pancreatic Cancer Pipeline Insight 2025” report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Pancreatic Cancer Pipeline Report to explore emerging therapies, key Pancreatic Cancer Companies, and future Pancreatic Cancer treatment landscapes @ Pancreatic Cancer Pipeline Outlook Report

Key Takeaways from the Pancreatic Cancer Pipeline Report

  • In April 2025, Nelson Yee announced phase II clinical study to investigate the efficacy and tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced pancreatic carcinoma (LAPC).
  • In April 2025, InxMed (Shanghai) Co. Ltd announced a study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.
  • DelveInsight’s Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
  • The leading Pancreatic Cancer Companies such as ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
  • Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Cancer Treatment Drugs

Pancreatic Cancer Emerging Drugs Profile

  • Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

  • Devimistat: Cornerstone Pharmaceuticals

CPI-613 (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Cancer progresses because it utilizes the mitochondria – the energy machinery of the cells – to generate the building blocks of the next tumor in order to fuel cancer growth and proliferation. Because it is designed to be highly specific, minimally toxic and effective against a wide variety of cancers, devimistat can be used for recurrent and hard-to-treat cancers, including on a chronic basis; it may also enhance the sensitivity of cancer cells to other treatment modalities, including chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of pancreatic cancer.

  • Masitinib: AB Science

Masitinib is a highly selective inhibitor of mast cell which gives therapeutic benefit by impacting on mast cell related remodeling of the tumor microenvironment. Masitinib is being developed in combination with chemotherapies for treatment of malignancies through its immunotherapeutic properties. The increased mast cell activity within the tumor microenvironment can promote disease progression through release of numerous pro-tumoral mediators, down-regulate the immune response to tumors, and modulation of macrophages towards a pro-tumoral state. The inhibition of the mast cell activity results in anti-tumor effect.

  • SBP-101: Panbela Therapeutics

Ivospemin (SBP-101) is a proprietary polyamine analogue that, due to its unique chemical structure. It inhibits both S-adenosylmethionine decarboxylase 1 (AMD1) and ornithine decarboxylase 1 (ODC1), two key enzymes in polyamine biosynthesis, lowering intracellular polyamine concentrations and slowing or preventing targeted cell growth and division. Ivospemin provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. The polyamine pathway at complementary junctions alter the disease. In particular, the drug have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system. Currently, the drug is in Phase II/III stage of its development for the treatment of pancreatic cancer.

  • TAS-102: Taiho Pharmaceutical Co., Ltd.

TAS-102 (Lonsurf) is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase. The drug is currently in Phase II trial for the pancreatic cancer.

  • RAIN-32: Rain Oncology

RAIN-32 (Milademetan), an oral small molecule, inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, and loss of an MDM2 regulator or other mechanism. The company commenced an additional Phase II trial in a multicenter, single arm, open-label, and basket trial evaluating milademetan for the treatment of MDM2-amplified advanced solid tumors (MANTRA-2) including pancreatic cancer.

  • IMX-110: Immix Biopharma

IMX-110 is a Tissue-Specific Therapeutic™ built on ImmixBio’s TME Normalization™ Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio’s TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110’s TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).

The Pancreatic Cancer Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
  • Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Pancreatic Cancer Drugs

Pancreatic Cancer Companies

ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Pancreatic Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Pancreatic Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pancreatic Cancer Market Drivers and Barriers

Scope of the Pancreatic Cancer Pipeline Report

  • Coverage- Global
  • Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
  • Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.

Which companies are leading the race in Pancreatic Cancer drug development? Find out in DelveInsight’s exclusive Pancreatic Cancer Pipeline Report—access it now! @ Pancreatic Cancer Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pancreatic Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Niraparib: Innovent Biologics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. CT041: CARsgen Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ONC 212: Oncoceutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pancreatic Cancer Key Companies
  21. Pancreatic Cancer Key Products
  22. Pancreatic Cancer- Unmet Needs
  23. Pancreatic Cancer- Market Drivers and Barriers
  24. Pancreatic Cancer- Future Perspectives and Conclusion
  25. Pancreatic Cancer Analyst Views
  26. Pancreatic Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Cancer Pipeline Appears Robust With 290+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Neuroendocrine Tumors Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Neuroendocrine tumors Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Neuroendocrine tumors pipeline landscape. It covers the Neuroendocrine Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Neuroendocrine Tumors Pipeline Outlook

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

  • In April 2025, Boehringer Ingelheim announced a study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.
  • DelveInsight’s Neuroendocrine Tumors pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Neuroendocrine Tumors treatment.
  • The leading Neuroendocrine Tumors Companies such as RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals and others.
  • Promising Neuroendocrine Tumors Pipeline Therapies such as lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.

Stay ahead with the most recent pipeline outlook for Neuroendocrine Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Treatment Drugs

Neuroendocrine Tumors Emerging Drugs Profile

  • RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors. Currently, the drug is in the Phase III stage of development to treat neuroendocrine tumors.

  • CAM2029: Camurus

CAM2029 is a long-acting subcutaneous depot of octreotide under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. Currently, the drug is in the Phase III stage of its development for the treatment of gastroentero pancreatic neuroendocrine tumors.

  • Ramucirumab: Eli Lilly and Company

Ramucirumab is a fully human IgG1 monoclonal antibody receptor antagonist designed to bind the extracellular domain of vascular endothelial growth factor (VEGF) receptor-2, thereby blocking the interaction of VEGF ligands (VEGF-A, VEGF-C, and VEGF-D) and inhibiting receptor activation. VEGF receptor-2 is considered a primary mediator of angiogenesis. When activated by VEGF ligands, VEGF receptor-2 promotes endothelial cell proliferation and survival, migration, and vascular permeability. Ramucirumab, which Lilly gained through its 2008 acquisition of ImClone Systems, is being investigated in clinical trials as monotherapy and in combination with other anticancer therapies for the treatment of multiple types of cancer. Currently, the drug is in the Phase II stage of its development for the treatment of neuroendocrine tumors.

  • Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

  • ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

The Neuroendocrine Tumors Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
  • Neuroendocrine Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market

Explore groundbreaking therapies and clinical trials in the Neuroendocrine Tumors Pipeline. Access DelveInsight’s detailed report now! @ New Neuroendocrine Tumors Drugs

Neuroendocrine Tumors Companies

RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals and others.

Neuroendocrine tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Neuroendocrine Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers

Scope of the Neuroendocrine Tumors Pipeline Report

  • Coverage- Global
  • Neuroendocrine Tumors Companies- RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals and others.
  • Neuroendocrine Tumors Pipeline Therapies- lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.
  • Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Neuroendocrine Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Neuroendocrine Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RYZ101: RayzeBio, Inc.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Ramucirumab: Eli Lilly and Company
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ADCT-701: ADC Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Neuroendocrine Tumors Key Companies
  21. Neuroendocrine Tumors Key Products
  22. Neuroendocrine Tumors- Unmet Needs
  23. Neuroendocrine Tumors- Market Drivers and Barriers
  24. Neuroendocrine Tumors- Future Perspectives and Conclusion
  25. Neuroendocrine Tumors Analyst Views
  26. Neuroendocrine Tumors Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuroendocrine Tumors Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Merkel Cell Carcinoma Pipeline Appears Robust With 14+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Merkel Cell Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Merkel Cell Carcinoma pipeline landscape. It covers the Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in the competitive pharmaceutical landscape with in-depth Pipeline Insights! Discover the latest advancements, key Merkel Cell Carcinoma Companies driving innovation, and the most promising Emerging Drugs shaping the future of treatment. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Merkel Cell Carcinoma Pipeline Outlook Report

Key Takeaways from the Merkel Cell Carcinoma Pipeline Insights Report

  • In April 2025, Replimiune Inc. announced a phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients. Patients will participate up to approximately 3 years including a 28-day screening period, up to approximately 1 year treatment period, and a 2-year follow-up period.
  • In April 2025, Ariceum Therapeutics GmbH conducted a study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • In April 2025, Aulos Bioscience, Inc. announced a phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin is determined, AU-007 plus aldesleukin will also be administered with avelumab or nivolumab.
  • DelveInsight’s Merkel Cell Carcinoma pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Merkel Cell Carcinoma treatment.
  • The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
  • Promising Merkel Cell Carcinoma Therapies such as Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.

Uncover Merkel Cell Carcinoma groundbreaking developments in the drug pipeline with our latest report! Gain exclusive insights into Merkel Cell Carcinoma Clinical Trials, regulatory updates, and Emerging Drugs across multiple therapeutic areas. Learn how leading Merkel Cell Carcinoma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Merkel Cell Carcinoma Clinical Trials Assessment

Merkel Cell Carcinoma Emerging Drugs Profile

  • Domatinostat: 4SC

Domatinostat is an orally administered histone deacetylase (HDAC) inhibitor with a unique mode of action that was designed to strengthen the body’s own anti-tumor immune response. Domatinostat “opens” the tumor microenvironment and encourages infiltration of immune cells into the tumor. To advance the development program, 4SC has also signed a drug supply agreement with Merck KGaA for avelumab (anti-PD-L1 antibody) to conduct a Phase II clinical trial of domatinostat in combination with avelumab in advanced-stage Merkel cell carcinoma (MCC) patients progressing on previous anti-PD-(L)1 monotherapy (MERKLIN 2).

  • Cavrotolimod: Exicure

Cavrotolimod (AST-008) is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. During the first half of 2019, five clinical trial sites were opened and began dosing patients for the Phase I/II clinical trial. The Phase 1b stage was an open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod (AST-008) injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). Exicure initiated the Phase II stage of the clinical trial with dose-expansion cohorts of intratumoral cavrotolimod in combination with approved checkpoint inhibitors to treat two cohorts of patients with locally advanced or metastatic MCC or CSCC.

The Merkel Cell Carcinoma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Merkel Cell Carcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Merkel Cell Carcinoma Treatment.
  • Merkel Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Merkel Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Merkel Cell Carcinoma market.

Explore the dynamic world of drug development with our latest Merkel Cell Carcinoma Pipeline Insights report! From early-stage research to late-phase Merkel Cell Carcinoma Clinical Trials, our analysis covers key Merkel Cell Carcinoma Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Merkel Cell Carcinoma Treatment Drugs

Merkel Cell Carcinoma Companies

ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.

Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Merkel Cell Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Stay updated with the latest Merkel Cell Carcinoma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Merkel Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Merkel Cell Carcinoma Companies- ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
  • Merkel Cell Carcinoma Therapies- Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.
  • Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Merkel Cell Carcinoma Emerging Drugs are set to revolutionize treatment landscapes? Which Merkel Cell Carcinoma Companies are leading the way in drug discovery? Find answers in our latest Merkel Cell Carcinoma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Merkel Cell Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Merkel Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Mid Stage Products (Phase II)
  7. Domatinostat: 4SC
  8. Drug profiles in the detailed report…..
  9. Early Stage Products (Phase I/II)
  10. XmAb18087: Xencor
  11. Drug profiles in the detailed report…..
  12. Preclinical stage products
  13. SNS-401-NG: Sensei Biotherapeutics
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Merkel Cell Carcinoma Key Companies
  17. Merkel Cell Carcinoma Key Products
  18. Merkel Cell Carcinoma- Unmet Needs
  19. Merkel Cell Carcinoma- Market Drivers and Barriers
  20. Merkel Cell Carcinoma- Future Perspectives and Conclusion
  21. Merkel Cell Carcinoma Analyst Views
  22. Merkel Cell Carcinoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/merkel-cell-carcinoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Merkel Cell Carcinoma Pipeline Appears Robust With 14+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Parallax 9/11 by Taylor Hopkinson: A Heart-Wrenching Journey Through Tragedy, Resilience, and the Aftermath of 9/11

Parallax 9/11 by Taylor Hopkinson: A Heart-Wrenching Journey Through Tragedy, Resilience, and the Aftermath of 9/11

7th May, 2025 – R. Taylor Hopkinson offers readers a moving and very personal narrative in her latest work, ‘Parallax 9/11’, which digs into one of the most horrific moments in modern history and analyzes the terrible impact of the September 11 attacks on individual lives and global consciousness. Taylor Hopkinson tells a gripping tale of grief, resiliency, and the never-ending struggle for justice while vividly capturing the destruction caused by the World Trade Center and the mayhem that followed on that tragic day.

Readers are immediately thrust into the center of the disaster as ‘Parallax 9/11’ begins with a striking portrayal of the World Trade Center prior to the assaults. Taylor Hopkinson examines the devastating impact of terrorism on a personal and societal level via the perspectives of Keith and Angela, two people whose lives are irrevocably changed by the events of 9/11. The novel’s emotional center is formed by Keith and Angela’s divergent lifestyles and developing connections, which provide a profoundly human viewpoint on the catastrophe.

Readers are taken on a trip through Angela’s sense of grief and loss as the novel progresses, as well as her attempt to start over in the wake of 9/11. The terrible impacts of the catastrophe on Angela and the others are poignantly shown throughout the story, demonstrating how their feeling of security and normalcy was abruptly destroyed. Deep personal loss characterizes Angela’s journey as she struggles with Keith’s passing and the engulfing anguish that follows.

Taylor Hopkinson doesn’t hold back when examining the intricate court battles that follow as Angela battles for justice and her son’s financial stability following Keith’s passing. The novel highlights the difficulties that many survivors and the families of victims encountered in their quest for justice, shedding light on the frequently chilly and unpleasant court system that Angela must navigate. Parallax 9/11 uses Angela’s tale to illustrate the long-lasting effects of 9/11 on people’s lives as well as more general thoughts on terrorism and the significance of remembering.

Angela’s tale is one of resiliency and hope despite her severe grief and obstacles. She gradually gains the strength to move forward with the help of friends and family, demonstrating the extraordinary resilience of the human spirit in the face of tragedy. Taylor Hopkinson’s account demonstrates the resilience of those who persevered, as well as the long-lasting effects of 9/11 on an individual and global level.

Beyond merely recounting the events of September 11, 2001, ‘Parallax 9/11’ is a meditation on the human cost of terrorism, the significance of remembering those who perished, and the grit needed to overcome the unfathomable loss. This book is a must-read for anybody curious about the lingering repercussions of 9/11 and the resilience of the human spirit because of Taylor Hopkinson’s vivid prose and genuinely human characters.

Don’t pass up the opportunity to order your book from Amazon now!

About the Author:

R. Taylor Hopkinson is a retired injury claims lawyer, poet, musician, singer, and writer. This docu-drama is his 2nd novel, his first being Puddle Creatures, published in 2023. He remains active in the law dealing with welfare and housing rights. He is Mancunian but now lives in Suffolk, U.K. He has 3 sons and 7 grandchildren.

Book Name: Parallax 9/11: Part 1: The Silent Assassin

Author Name: R. Taylor Hopkinson

ISBN Number: 978-1917438568

Kindle Version: Click Here

Paperback Version: Click Here

Hardcover Version: Click Here

Media Contact
Company Name: Author Book Publications
Email: Send Email
Phone: +1-213-734-5719
Address:2333 Alexandria Dr
City: Lexington
State: Kentucky
Country: United States
Website: https://authorbookpublications.com/

Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape. Click here to read more @ Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Renal Cell Carcinoma Pipeline Report

  • In May 2025, Merck Sharp & Dohme LLC announced a study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in Part 1.
  • In May 2025, Karie Runcie announced a Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of XL092 alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
  • DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
  • The leading Renal Cell Carcinoma Companies such as AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
  • Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.

Discover groundbreaking developments in Renal Cell Carcinoma therapies! Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Renal Cell Carcinoma Clinical Trials Assessment

Renal Cell Carcinoma Emerging Drugs Profile

  • CM082: Betta Pharmaceuticals

CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma.

  • TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.

  • IPI-549: Infinity Pharmaceuticals

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.

  • CMN-001: ColImmune

Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.

The Renal Cell Carcinoma Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cell Carcinoma Treatment.
  • Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cell Carcinoma market.

Stay informed about the Renal Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs

Renal Cell Carcinoma Companies

AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

Renal Cell Carcinoma Products have been categorized under various Molecule types such as

  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type

Transform your understanding of the Renal Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Renal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
  • Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
  • Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies

Table of Content

  1. Introduction
  2. Renal Cell Carcinoma Executive Summary
  3. Renal Cell Carcinoma: Overview
  4. Renal Cell Carcinoma Pipeline Therapeutics
  5. Renal Cell Carcinoma Therapeutic Assessment
  6. Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Renal Cell Carcinoma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. IPI-549: Infinity Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. AVB-S6-500: Aravive Inc.
  17. Drug profiles in the detailed report…..
  18. Preclinical Stage Products
  19. Drug Name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Renal Cell Carcinoma Key Companies
  23. Renal Cell Carcinoma Key Products
  24. Renal Cell Carcinoma – Unmet Needs
  25. Renal Cell Carcinoma – Market Drivers and Barriers
  26. Renal Cell Carcinoma – Future Perspectives and Conclusion
  27. Renal Cell Carcinoma Analyst Views
  28. Renal Cell Carcinoma Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight